APRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aprea Therapeutics Inc (APRE) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has shown positive momentum with a 12.35% regular market gain and promising clinical trial results for its lead drug candidate APR-1051. Insider buying activity and recent patent enhancements further support the stock's potential. While financial performance is weak, the company's focus on its promising pipeline and positive analyst sentiment make it a compelling long-term investment.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting some caution. The stock has broken through R1 (0.797) and is approaching R2 (0.866), showing strong upward momentum.
Positive clinical trial results for APR-1051, including a 50% tumor shrinkage and a second partial response in advanced endometrial cancer patients. Insider buying activity has increased significantly (147.37% over the last month). Recent patents provide exclusivity for key programs until 2045.
Bearish moving averages indicate some technical resistance.
The company's financials for 2025/Q3 show a sharp decline in revenue (-99.48% YoY) and net income (-21.44% YoY). EPS also dropped by -26.56% YoY. However, gross margin remains at 100%, indicating operational efficiency despite revenue challenges.
Analysts remain optimistic about the company's potential, with Wedbush maintaining an Outperform rating and H.C. Wainwright keeping a Buy rating. Both firms have lowered price targets recently due to dilution but highlight the promising clinical data for APR-1051 as a key driver of future growth.
